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Abstract
Malignant melanoma can metastasize to virtually any organ of the body. The aggressiveness is
determined by the primary site, depth of dermal invasion, presence or absence of ulceration,
lymphovascular infiltration and regional lymph node involvement. We report a case of a pregnant
woman with a previous history of stage 3 melanoma who presented with cardiac metastasis and
placental melanoma infiltration. A review of literature on cardiac and placental involvement of
melanoma is also provided.
Background
Malignant melanoma is considered to be a highly aggres-
sive cancer. Post mortem studies have shown that
melanoma can metastasize to any organ of the body, with
50% of the patients found to have cardiac involvement
[1]. However only 2% of patients with metastatic
melanoma to the heart are diagnosed antemortem [2], as
most patients do not have any cardiac symptoms.
Melanoma is also unique in that it is the most common
cancer to metastasize to the placenta [3].
We report a pregnant woman with invasive melanoma
who presented with metastasis in the right atrium and pla-
cental melanoma infiltration. The balance of surgery,
chemotherapy and obstetric management in this case is
challenging.
Case report
A 32 year old woman, initially presented at the age of 27
with stage 3 malignant melanoma. The patient underwent
wide local excision of a 1.76 mm Breslow thickness
melanoma from the right thigh and shortly afterwards
was found to have a mass in the right groin. She under-
went right inguinal block dissection, with 2 of 6 lymph
nodes positive for melanoma. CT scan showed no evi-
dence of other disease sites. The patient had adjuvant high
dose interferon (20 MU/m2/d IV 5 days/wk × 4 weeks fol-
lowed by 10 MU/m2 SC thrice weekly × 48 weeks) which
was discontinued after nearly 7 months due to persistent
neutropenia.
When aged 31 and 19 weeks pregnant, the patient noticed
a mass beneath her jaw consistent with right submandib-
ular lymph gland enlargement and had exertional dyps-
noea. A CT scan revealed a pericardial effusion of 1 cm
depth. A transthoracic echocardiogram showed a right
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good preservation of ventricular function.
An MRI scan of the heart confirmed the mass to be more
extensive measuring 8 cm in size and extending into the
superior vena cava (fig 1). An echocardiogram guided
biopsy of the mass (fig 2A) revealed necrotic tumour with
associated thrombus and adjacent normal myocardium.
The viable tumour was composed of moderately pleomor-
phic epitheliod melanocyes (S100/HMB45 positive) with
enlarged pleomorphic nuclei and prominent nucleoli.
The patient was keen to continue with pregnancy and after
careful consideration was commenced on palliative chem-
otherapy with dacarbazine (800 mg/m2 IV every 3 weeks).
The decision was to deliver the baby early by elective Cae-
sarean section at 34 weeks of gestation considering the
risk of sudden cardiac death of the mother, which would
likely be associated with fetal demise. After 2 cycles of
dacarbazine, an echocardiogram showed that the atrial
mass was smaller.
However an emergency Caesarean section was performed
at 31 weeks gestation because of ante-partum haemor-
rhage. The baby delivered weighed 1.5 kg with no signifi-
cant problems in the neonatal period. Histological
examination of the placental tissue showed unremarkable
cord and membranes. The placental bed showed an early
third trimester architecture with good villous develop-
ment. Focally there were groups of viable epitheliod
melanocytes, similar to the cardiac tissues with associated
thrombus (fig 2B). Immunohistochemistry revealed
S100, HMB45 and melan A positivity, consistent with
melanoma. As there had been a response on the echocar-
diogram, we decided to proceed to 8 cycles of dacarbazine
chemotherapy. Following this, an MRI scan of the heart
showed less tumour bulk with a maximum dimension of
less than 2 × 3 cm. Clinically the patient had no dyspnoea
on exertion. The right mandibular lymph gland enlarge-
ment was persistent and a selective neck dissection was
done. This showed central degeneration in one lymph
node with a peripheral rim of fibroconnective tissue
showing melanin deposition, representing a response to
chemotherapy.
Despite the metastatic nature of her disease, this patient
remains well and is currently awaiting opinion for cardiac
HistopathologyFigure 2
Histopathology: A. Endomyocardial biopsy showed pleo-
morphic malignant melanoma(mm) with associated necrosis 
(original magnification × 200). B. Placental tissue shows vil-
lous tissue(v) with foci of malignant melanoma(mm) (original 
magnification × 200).
MRI of the heart showing low signal density in the right atrial (arrowed) representing metastasisFigure 1
MRI of the heart showing low signal density in the right atrial 
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ease.
Discussion
Metastatic melanoma of the heart is generally a part of
widespread tumour dissemination. The surgical manage-
ment of these patients varies depending on presence or
absence of extracardiac involvement and also the extent of
the cardiac tumour. If anatomically feasible, complete
resection with reconstruction should be attempted [4].
Indications for complete surgical resection are patients
with a preoperative Karnofsky performance status of more
than 80%, minimal extracardiac disease, or a deteriorating
clinical picture due to cardiac symptoms [4]. In extensive
disease, surgical debulking may be considered as a pallia-
tive therapeutic option.
Chemotherapy was considered to be the best available
option of treatment in this case, considering the risk of a
major surgical procedure on the viability of the fetus.
There are some previously published reports of the use of
chemotherapy for metastatic melanoma in pregnancy.
Harkin et al. reported the use of dacarbazine in the 3rd tri-
mester which induced dramatic remission [5]. Another
report suggested that combination chemotherapy which
included dacarbazine when used in the 2nd trimester did
not interfere with the maturation and delivery of the
infant [6]. No congenital anomalies in infants born to
women treated with dacarbazine have been reported after
treatment during the 2nd or 3rd trimester.
Sorafenib an oral targeted agent and a multi-kinase inhib-
itor, is well tolerated but has little or no anti tumour activ-
ity when used alone in advanced melanoma [7]. Ongoing
trials in advanced melanoma are evaluating sorafenib in
combination therapies. However this agent has not been
studied in pregnant women and is not recommended for
use in pregnancy.
Placental and fetal metastasis related to cancers have been
documented before, the most common being melanoma
[8]. The risk of development of melanoma in the fetus
with placental involvement is approximately 22%. Babies
born with placental metastasis should therefore be con-
sidered high risk and monitored closely. Infants develop-
ing clinical evidence of maternally derived metastasis
have poor prognosis with mortality reaching 100% and
death typically occurring within 3 months of diagnosis
[8].
Some difficult ethical issues arise from this case. Firstly,
because of poor median survival of 6 months in pregnant
women with metastatic melanoma which may make them
seriously ill before term, putting the life of the fetus at risk
[9]. However, recent reports suggest that there is no signif-
icant difference in outcome and survival rate between
pregnant and non-pregnant women with melanoma [10].
Secondly, there is an increased risk of melanoma in the
infant and when found the prognosis is invariably poor.
Maternal factors associated with an unfavourable infant
prognosis include maternal age less than 30 years, primi-
parity, disease onset more than 3 years before current
pregnancy, nodal metastasis before pregnancy, more than
three sites of metastatic foci during the third trimester, pri-
mary site of the leg, and maternal death within 1 month
of birth [3]. Counselling of pregnant women who develop
metastatic melanoma is vital. The patient and carers need
support in their decisions about whether to continue with
pregnancy and which treatment options to pursue.
Conclusion
Metastatic melanoma can sometimes be associated with a
good outcome as illustrated in this case. Chemotherapy is
a reasonable alternative to surgery when used for disease
control in an obstetric setting. A multidisciplinary team
approach is vital in management of these complex cases.
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